🚀 VC round data is live in beta, check it out!
INmune Bio Valuation Multiples
Discover revenue and EBITDA valuation multiples for INmune Bio and similar public comparables like Advicenne, Celularity, BioXcel Therapeutics, Jiangsu Wuzhong Pharmaceutical and more.
INmune Bio Overview
About INmune Bio
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
Founded
2015
HQ
Employees
22
Website
Sectors
Financials (LTM)
EV
$8M
INmune Bio Financials
INmune Bio reported last 12-month revenue of $49K.
In the same LTM period, INmune Bio generated had net loss of ($45M).
Revenue (LTM)
INmune Bio P&L
In the most recent fiscal year, INmune Bio reported revenue of $14K and EBITDA of ($43M).
INmune Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $49K | XXX | $14K | XXX | XXX | XXX |
| EBITDA | — | XXX | ($43M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (304536%) | XXX | XXX | XXX |
| EBIT Margin | (78428%) | XXX | (304454%) | XXX | XXX | XXX |
| Net Profit | ($45M) | XXX | ($42M) | XXX | XXX | XXX |
| Net Margin | (90980%) | XXX | (300586%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
INmune Bio Stock Performance
INmune Bio has current market cap of $35M, and enterprise value of $8M.
Market Cap Evolution
INmune Bio's stock price is $1.31.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8M | $35M | 0.0% | XXX | XXX | XXX | $-1.58 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialINmune Bio Valuation Multiples
INmune Bio trades at 165.7x EV/Revenue multiple, and (0.2x) EV/EBITDA.
EV / Revenue (LTM)
INmune Bio Financial Valuation Multiples
As of March 18, 2026, INmune Bio has market cap of $35M and EV of $8M.
Equity research analysts estimate INmune Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
INmune Bio has a P/E ratio of (0.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $35M | XXX | $35M | XXX | XXX | XXX |
| EV (current) | $8M | XXX | $8M | XXX | XXX | XXX |
| EV/Revenue | 165.7x | XXX | 583.8x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.2x) | XXX | XXX | XXX |
| EV/EBIT | (0.2x) | XXX | (0.2x) | XXX | XXX | XXX |
| P/E | (0.8x) | XXX | (0.8x) | XXX | XXX | XXX |
| EV/FCF | (4.7x) | XXX | (3.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified INmune Bio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
INmune Bio Margins & Growth Rates
INmune Bio's revenue in the last 12 month grew by 2763%.
INmune Bio's revenue per employee in the last FY averaged $0.0M.
INmune Bio Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2763% | XXX | 346% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (304536%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 43% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 19234% | XXX | 67736% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 42623% | XXX | 236900% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 304636% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
INmune Bio Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Advicenne | XXX | XXX | XXX | XXX | XXX | XXX |
| Celularity | XXX | XXX | XXX | XXX | XXX | XXX |
| BioXcel Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Jiangsu Wuzhong Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Pluri | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
INmune Bio M&A Activity
INmune Bio acquired XXX companies to date.
Last acquisition by INmune Bio was on XXXXXXXX, XXXXX. INmune Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by INmune Bio
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialINmune Bio Investment Activity
INmune Bio invested in XXX companies to date.
INmune Bio made its latest investment on XXXXXXXX, XXXXX. INmune Bio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by INmune Bio
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout INmune Bio
| When was INmune Bio founded? | INmune Bio was founded in 2015. |
| Where is INmune Bio headquartered? | INmune Bio is headquartered in United States. |
| How many employees does INmune Bio have? | As of today, INmune Bio has over 22 employees. |
| Who is the CEO of INmune Bio? | INmune Bio's CEO is Raymond J. Tesi. |
| Is INmune Bio publicly listed? | Yes, INmune Bio is a public company listed on Nasdaq. |
| What is the stock symbol of INmune Bio? | INmune Bio trades under INMB ticker. |
| When did INmune Bio go public? | INmune Bio went public in 2019. |
| Who are competitors of INmune Bio? | INmune Bio main competitors are Advicenne, Celularity, BioXcel Therapeutics, Jiangsu Wuzhong Pharmaceutical. |
| What is the current market cap of INmune Bio? | INmune Bio's current market cap is $35M. |
| What is the current revenue of INmune Bio? | INmune Bio's last 12 months revenue is $49K. |
| What is the current revenue growth of INmune Bio? | INmune Bio revenue growth (NTM/LTM) is 2763%. |
| What is the current EV/Revenue multiple of INmune Bio? | Current revenue multiple of INmune Bio is 165.7x. |
| Is INmune Bio profitable? | No, INmune Bio is not profitable. |
| What is the current net income of INmune Bio? | INmune Bio's last 12 months net income is ($45M). |
| What is the current FCF of INmune Bio? | INmune Bio's last 12 months FCF is ($2M). |
| What is INmune Bio's FCF margin? | INmune Bio's last 12 months FCF margin is (3533%). |
| What is the current EV/FCF multiple of INmune Bio? | Current FCF multiple of INmune Bio is (4.7x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.